Результаты поиска

Forecasting drug utilization and expenditure in a metropolitan health region.

BackgroundNew pharmacological therapies are challenging the healthcare systems, and there is an increasing need to assess their therapeutic value in relation to existing alternatives as well as their potential budget impact. Consequently, new models to introduce drugs in healthcare are urgently needed. In the metropolitan health region of Stockholm, Sweden, a model has been developed including early warning (horizon scanning), forecasting of drug utilization and expenditure, critical drug evaluation as well as structured programs for the introduction and follow-up of new drugs. The aim of this

Совпадение в полном тексте источника
… rational use of new medicines across European health care systems Eur J Clin Pharmacol 2008 64 1137 8 10.1007/s00228-008-0537-z 18688606 Askling J Fored CM Geborek P Jacobsson LT van Vollenhoven R Feltelius N Lindblad S Klareskog L Swedish registers to examine drug safety and clinical issues in RA Ann Rheum …

Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in complex regional pain syndrome.

BackgroundCollaborative efforts of physicians and basic scientists are often necessary in the investigation of complex disorders. Difficulties can arise, however, when large amounts of information need to reviewed. Advanced information retrieval can be beneficial in combining and reviewing data obtained from the various scientific fields. In this paper, a team of investigators with varying backgrounds has applied advanced information retrieval methods, in the form of text mining and entity relationship tools, to review the current literature, with the intention to generate new insights into th

Совпадение в полном тексте источника
… with long-acting intramuscular corticosteroids J Hand Surg [Am] 1996 21 667 670 8842963 10.1016/S0363-5023(96)80023-2 Manicourt DH Brasseur JP Boutsen Y Depreseux G Devogelaer JP Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity Arthritis Rheum …

Influence of the TGF-β Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions.

The balance between bone forming cells (osteoblasts/osteocytes) and bone resorbing cells (osteoclasts) plays a crucial role in tissue homeostasis and bone repair. Several hormones, cytokines, and growth factors-in particular the members of the TGF-β superfamily such as the bone morphogenetic proteins-not only regulate the proliferation, differentiation, and functioning of these cells, but also coordinate the communication between them to ensure an appropriate response. Therefore, this review focuses on TGF-β superfamily and its influence on bone formation and repair, through the regulation of

Purinergic Signalling: Therapeutic Developments.

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990's when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and the

Neurological complications of current and emerging CAR-T cell therapies.

Harnessing an individual patient's immune system to enhance anti-tumor responses has been a long-standing goal in oncology. Multiple immune modulating or immune enhancing therapies have been FDA approved or are under development, utilizing varying strategies to engage the patient's own immune system. One such therapy is chimeric antigen receptor T-cell therapy (CAR-T), in which T-cells are genetically engineered to target specific antigens present on tumor cells. Multiple CAR-T products are currently approved for clinical use, with impressive and durable responses seen in hematologic cancers.

Совпадение в полном тексте источника
… BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial Ann Rheum Dis 83 10 2024 Oct 1 1304 1314 10.1136/ard-2024-225785 PubMed PMID: 38777376 38777376 91 Granit V. Benatar M. Kurtoglu M. Miljković M.D. Chahin N. Sahagian G. …

The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.

As an important means of modern cancer treatment, targeted therapy has significant efficacy, but cardiac toxicity cannot be ignored. From subclinical myocardial injury to severe heart failure (HF), it poses significant challenges to the long-term survival and quality of life of patients. This article summarizes the impact of targeted therapy drugs on cardiac function and their mechanisms, including cardiomyocyte damage, myocardial hypertrophy, and HF, and conducts in-depth research into potential molecular mechanisms. These include direct cardiomyocyte damage through targeted pathway inhibitio

Совпадение в полном тексте источника
… Semin Arthritis Rheum 2024;66:152440. 10.1016/j.semarthrit.2024.152440 72. Cool A, Nong T, Montoya S, et al. BTK inhibitors: past, present, and future. Trends Pharmacol Sci 2024;45:691-707. 10.1016/j.tips.2024.06.006 73. Jiang VC, Liu Y, Lian J, et al. …

Expression and Clinical Significance of BCL2 Interacting Protein 3 Like (BNIP3L) in Serum of Patients with MM.

BackgroundBNIP3L regulates mitophagy and apoptosis, and its dysregulation is closely linked to the development and progression of cancers. Studies have shown that BNIP3L is valuable for assessing tumor progression and prognosis. This study aims to investigate the diagnostic and prognostic significance of serum BNIP3L levels in multiple myeloma (MM).MethodsThe serum level of BNIP3L were measured in 152 MM patients and 158 healthy controls by Enzyme-Linked Immunosorbent Assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic ability of MM. The

Совпадение в полном тексте источника
… Ann Rheum Dis . 2009 ; 68 ( 2 ): 246 – 248 . doi: 10.1136/ard.2008.092031 18801759 6. Varzieva VG , Mesonzhnik NV , Ilgisonis IS , Belenkov YN , Kozhevnikova MV , Appolonova SA . Metabolomic biomarkers of multiple myeloma: a systematic review . …

Бремя множественной миеломы в азиатских странах 1990 в адрес 2021 и прогнозирование тенденций 2050:: анализ, основанный на Глобальном исследовании бремени болезней 2021.

Множественная миелома (ММ) создает растущую угрозу для здоровья населения во всем мире, причем региональные различия в бремени болезней становятся все более заметными. Являясь самым густонаселенным континентом, Азия переживает быстрые демографические и социально-экономические изменения и играет решающую роль в формировании эволюционной траектории глобального бремени ММ. Цель этого исследования заключается в оценке бремени болезней, связанных с множественной миеломой в азиатских странах. 1990 в адрес 2021Данные этого исследования были получены на основе исследования глобального бремени болезней

Совпадение в полном тексте источника
… Ann Rheum Dis . ( 2020 ) 79 : 1014 – 22 . 10.1136/annrheumdis-2020-217050 32414807 29. Nguyen HV Naeem MA Wichitaksorn N Pears R . A smart system for short-term price prediction using time series models. Comput. Electrical Eng. ( 2019 ) 76 : 339 – 52 . 10.1016/j.compeleceng.2019.04.013 30. …

Review of the Longitudinal Management of Autoimmune Encephalitis, Potential Biomarkers, and Novel Therapeutics.

Purpose of reviewIncreasing awareness and earlier diagnosis of autoimmune encephalitis (AE) have led to a greater number of patients being cared for longitudinally by neurologists. Although many neurologists are now familiar with the general approach to diagnosis and acute immunosuppression, this review aims to provide neurologists with guidance related to management beyond the acute phase of disease, including long-term immunosuppression, monitoring, potential biomarkers of disease activity, outcome measures, and symptom management.Recent findingsObservational studies in AE have demonstrated

Совпадение в полном тексте источника
… Ann Rheum Dis. 2017 ; 76 ( 3 ): 543 - 546 . doi: 10.1136/ANNRHEUMDIS-2016-210002 27474764 24. Lünemann JD , Nimmerjahn F , Dalakas MC . Intravenous immunoglobulin in neurology--mode of action and clinical efficacy . …

Interventional Procedures for Vertebral Diseases: Spinal Tumor Ablation, Vertebral Augmentation, and Basivertebral Nerve Ablation-A Scoping Review.

Low back pain is consistently documented as the most expensive and leading cause of disability. The majority of cases have non-specific etiologies. However, a subset of vertebral diseases has well-documented pain generators, including vertebral body tumors, vertebral body fractures, and vertebral endplate injury. Over the past two decades, specific interventional procedures targeting these anatomical pain generators have been widely studied, including spinal tumor ablation, vertebral augmentation, and basivertebral nerve ablation. This scoping review summarizes safety and clinical efficacy and

Совпадение в полном тексте источника
… A systematic review of the global prevalence of low back pain Arthritis Rheum. 2012 64 2028 2037 10.1002/art.34347 22231424 3. Dieleman J.L. Cao J. Chapin A. Chen C. Li Z. Liu A. Horst C. Kaldjian A. Matyasz T. Scott K.W. …

Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.

Background: Multiple myeloma (MM) is the second most common hematological malignancy, which is still incurable and relapses inevitably, highlighting further understanding of the possible mechanisms. Side population (SP) cells are a group of enriched progenitor cells showing stem-like phenotypes with a distinct low-staining pattern with Hoechst 33342. Compared to main population (MP) cells, the underlying molecular characteristics of SP cells remain largely unclear. This bioinformatics analysis aimed to identify key genes and pathways in myeloma SP cells to provide novel biomarkers, predict MM

Совпадение в полном тексте источника
… Ann Rheum Dis. 2012;71:2028–34. doi: 10.1136/annrheumdis-2012-201390. 51. Maiti AK, Kim-Howard X, Motghare P, Pradhan V, Chua KH, Sun C. et al. Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM. …

Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.

Denosumab is a breakthrough biological drug approved by the Food and Drug Administration and European Medicines Agency for the treatment of osteoporosis in 2010. It is a fully human monoclonal antireceptor activator of nuclear factor kappa-B ligand antibody, which inhibits the activity of osteoclasts, resulting in an antiresorptive effect with a significant increase in bone mineral density. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial, comparing denosumab with no treatment in 7868 women with postmenopausal osteoporosis, showed an important reduc

Совпадение в полном тексте источника
… Atrthritis Rheum. 2008;58(6):1687–1695. doi: 10.1002/art.23461. 44. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018–2026. doi: 10.1016/S0140-6736(02)08827-X. 45. Recker RR, Marin F, Ish-Shalom S, et al. …

Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.

Monoclonal antibodies targeting specific cell surface antigens have emerged as a promising therapeutic approach for acute myeloid leukemia (AML), thus widening the treatment landscape of this heinous disease. These antibodies have been designed to selectively target and eliminate leukemic cells while limiting damage to the normal hematopoietic counterpart. Among the potential targets on AML cells, CD33, CD123, and CD47 have shown the major potential in preclinical and clinical trials. Additionally, conjugation of monoclonal antibodies with cytotoxic agents has further enhanced their therapeuti

Совпадение в полном тексте источника
… Arthritis Rheum. 2004;50:2580–2589. doi: 10.1002/art.20430. 46. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522–525. doi: 10.1038/321522a0. 47. …

Exploring the Emerging Association Between Immune Checkpoint Inhibitors and Thrombosis.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their association with thrombosis presents significant clinical challenges. Patients with cancer already exhibit elevated risks for venous thromboembolism and arterial thrombosis, with treatment modalities like chemotherapy further exacerbating this risk. Emerging evidence suggests that ICIs contribute to thrombotic events through multifactorial mechanisms, including immune dysregulation, T cell activation, endothelial dysfunction, elevated tissue factor expression, and impaired fibrinolysis. Additional risk factors

Совпадение в полном тексте источника
… Rheum. Dis. Clin. N. Am. 2024;50:147–159. doi: 10.1016/j.rdc.2024.01.001. 21. Pizuorno Machado A., Shatila M., Liu C., Wang J., Altan M., Zhang H.C., Thomas A., Wang Y. …

Interleukin-32: a Pandora's box in human immunodeficiency virus infection.

Human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS), has been estimated to infect around 40.8 million people globally. This virus can persist and thrive in the presence of antiretroviral therapy, which is a major obstacle to HIV eradication. Therefore, understanding host immunological factors that underlie HIV persistence and pathogenesis can lead to the development of immunotherapeutic interventions. Interleukin-32 (IL-32) is an orphan cytokine with multiple isoforms and a complex signal transduction pathway that transmits through non-specific receptors.

Совпадение в полном тексте источника
… Arthritis Rheum . ( 2009 ) 60 : 678–85 . doi: 10.1002/art.24299 , PMID: 19248119 42 Hasegawa H Thomas HJ Schooley K Born TL . Native il-32 is released from intestinal epithelial cells via A non-classical secretory pathway as A membrane-associated protein . …

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.

Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, con

Совпадение в полном тексте источника
… Rheum. Dis. 2018 77 1516 1523 10.1136/annrheumdis-2017-212916 29945920 PMC6161670 93. Lonial S. Popat R. Hulin C. Jagannath S. Oriol A. Richardson P.G. Facon T. Weisel K. Larsen J.T. Minnema M.C. …

Polyphenolic natural products as photosensitizers for antimicrobial photodynamic therapy: recent advances and future prospects.

Antimicrobial photodynamic therapy (aPDT) has become a potent contender in the fight against microbial infections, especially in the context of the rising antibiotic resistance crisis. Recently, there has been significant interest in polyphenolic natural products as potential photosensitizers (PSs) in aPDT, given their unique chemical structures and inherent antimicrobial properties. Polyphenolic natural products, abundant and readily obtainable from natural sources, are generally regarded as safe and highly compatible with the human body. This comprehensive review focuses on the latest develo

Совпадение в полном тексте источника
… It is extracted from traditional Chinese medicine (TCM) plants such as Aloe vera , Rheum officinale Baill. , Rumex patientia Linn. , Cassia mimosoides L. and Polygonum multiflorum Thunb ( 115 , 116 ). …

The role of MSCs and CAR-MSCs in cellular immunotherapy.

Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells carrying CARs, cell dysfunction or exhaustion, relapse of disease, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, low efficacy against solid tumors and immunosuppression by the tumor microenvironment. Another important cell therapy regimen involves mesenchymal stem c

Совпадение в полном тексте источника
… Arthritis Rheum. 2010;62(9):2776–2786. doi: 10.1002/art.27560. 43. Mázló A, Kovács R, Miltner N, Tóth M, Veréb Z, Szabó K, Bacskai I, Pázmándi K, Apáti Á, Biro T, et al. …

Autoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications.

Recent advances in medical genetics elucidated the background of diseases characterized by superficial dermal and epidermal inflammation with resultant aberrant keratosis. This led to introducing the term autoinflammatory keratinization diseases encompassing entities in which monogenic mutations cause spontaneous activation of the innate immunity and subsequent disruption of the keratinization process. Originally, autoinflammatory keratinization diseases were attributed to pathogenic variants of CARD14 (generalized pustular psoriasis with concomitant psoriasis vulgaris, palmoplantar pustulosis

Совпадение в полном тексте источника
… A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis) Ann Rheum Dis. 2017;76(7):1191–1198. doi: 10.1136/annrheumdis-2016-210021. 134. …

Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer.

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine implicated in the pathogenesis of inflammation and cancer. It is produced by various cells and circulating MIF has been identified as a biomarker for a range of diseases. Extracellular MIF mainly binds to the cluster of differentiation 74 (CD74)/CD44 to activate downstream signaling pathways. These in turn activate immune responses, enhance inflammation and can promote cancer cell proliferation and invasion. Extracellular MIF also binds to the C-X-C chemokine receptors cooperating with or without CD74 to activate chemokine

Совпадение в полном тексте источника
… Arthritis Rheum. 44, 1782–1785. 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-# Esumi N., Budarf M., Ciccarelli L., Sellinger B., Kozak C. A., Wistow G. (1998). Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF. Mamm. …